Hisamitsu, Shire sales and marketing update

Hisamitsu's Noven Pharmaceuticals Inc. subsidiary will reacquire ADHD drug Daytrana methylphenidate transdermal system (formerly MethylPatch) from Shire. Shire said it will receive consideration from Noven based on a percentage of Noven's future sales, which will be accounted for as deferred consideration. Specific details were not disclosed.

Shire attributed the decision in part to a usability issue associated with removing the release liner. It also said its market share for Daytrana in the ADHD market was less than 1%. The transdermal methylphenidate patch had 1H09 sales of $34.7 million. The deal is expected to close on Oct. 1. ...